FDA approves Sanofi-Aventis Nasacort AQ for children

WASHINGTON The Food and Drug Administration has approved a drug for treating seasonal and perennial allergies in children aged 2 to 5.

The drug, Sanofi-Aventis Nasacort AQ, received approval for the new usage Friday, according to an FDA statement. Nasacort AQ is a corticosteroid with the generic name triamcinolone acetonide and is available as a nasal spray.